In conclusion, our data provide the first evidence for ABO-IA using Glycosorb® ABO immunoadsorption columns as an efficient and safe therapeutic option for the treatment of PRCA after ABO-incompatible allogeneic HSCT. This evidence concerns the gene ABO and pure red-cell aplasia.